Avantika Mathure

BRANDS MANAGED : Utryp, PolyMxB, Ampholip, Equirab, Tetglob

BUSINESS VOLUME MANAGED : Rs. 110 Crs

REGIONS MANAGED : 6 Regions and 44 countries

NOTEWORTHY ACHIEVEMENTS:

• Successfully launch Utryp in the Kenya and Ukraine
• Spearheaded the Launch PolyMxB in Philippines, Nigeria, Mauritius
• Collaborations with national bodies like ISCCM & FISF & conducting flagship CME’s with KOL’s.
• Initiation of a online KOL interface – Web meets
• Developed Compact digitized marketing tools for better strategy execution
• Formation of CARE forum for rabies awareness
• Formation of Global Advisory panel for focus brands
• Built brand awareness through marketing
• Developed creative sales tools, including Product presentations, Medical presentations & periodic product trainings etc.
• Reduced marketing costs by monitoring budgets
• Develop Brand Advocates through continuous scientific engagement

BRANDS MANAGED : Colymonas, Inem, Dapmicin,

Recent launch:- Paxyb(Polymyxin B) & Colymonas 4.5 MIU

BUSINESS VOLUME MANAGED : Rs.35 Crs FIELD STRENGTH : 86 TBMs; 13 ZSM’s; 2 SM;1BH

NOTEWORTHY ACHIEVEMENTS:

Critical care

§ Clocked 1 cr primary and 50 lakhs sec in the first month of launch of Colymonas 4.5 MIU due to strong prelaunch strategy.

§ Paxyb became No.1 in Polymyxin B market with a share of over 33% in Nov 15 MAT

o Initiation of Indian Perspective studies of Polymyxin B

o Zonal Advisory Boards

o Best of Polymyxins – Proceedings of Polymyxins 2015 conference (San diego)

§ Vol growth of 50% for Colymonas.

§ Won Star Award for exemplary performance in 2014-2015 & 2016-17

§ Initiated, building guidelines for colistin usage-Indian context

§ Procured License for colistin in Inhalation use in coordination with the PPIC & licensing team

§ Successfully initiated & executed the following one of its kind Activities

· International speaker program @ 4 locations covering 720 drs

· Survey on Prevalance of super bugs in India – 1000 drs enrolled –published

· Indian study on Pk/Pd parameters on colistin @ 4 centres

· Poster presentation on Colistin @ Criticare 2015

· Co-ordinated for publishing a study on efficacy & safety of colistin in JGID

· Paper presentation @ ECCMID 2015 on Colistin

· Poster Presentation on PEM-Imipenem cilastatin @ Criticare 2014

· Comprehensive & Handy solution for Easy Dose calculation

· Conducted 250 Departmental CMEs & 100 paramedic training programme pan India

§ Dapmicin became No.1 brand in daptomycin mkt with market share 40.81% in Nov 14 MAT.

§ Formation of An Online Critical Care forum & a mobile app for handy solution in ICU

BRANDS MANAGED : Collodermis, Plasmanate, Albumin

Recent launch: - Casponex

Additional Brands :- Amphomul, Gamma IV

BUSINESS VOLUME MANAGED : Rs.14 Crs + 30 Crs FIELD STRENGTH : 168 ASE’s; 35 ASM’s; 15 ZSM’s

NOTEWORTHY ACHIEVEMENTS:

§ Successfully co-ordinated BSV’s entry into the Wound Management segment through the launch of Collodermis (Dry collagen sheets).

§ Initiated an E-learning Module for the Sales team for Product Knowledge enhancement.

§ Feasibility studies for Albumin LS, Interferon Alpha 2B, and Role of Microbiology in Critical care.

§ Indication Expansion for Plasmanate and Plavolex into the IVF segment.

§ Designing and implementation of Oncology Training Program for Dr. Reddy’s at Green Room Media - Conducted 60 programs All India within 8 months.

BRANDS MANAGED: Mox, Mox-Clav, Roles, Zanocin OD, Ultrazox, Fleet

BUSINESS VOLUME Generated: Rs. 2 lakhs/month

NOTEWORTHY ACHIEVEMENTS:

§ Brand-Co-ordinator for Ultrazox (Pain killer)

§ 60% increase on the existing business

§ Inclusion of Fleet into Hinduja Formulary

§ Inclusion of MOX-CLAV as a brand in the treatment protocol of Orthopaedic department of Sion Hospital